Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $50.64, for a total value of $156,984.00. Following the transaction, the insider now owns 42,246 shares in the company, valued at $2,139,337.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total value of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total value of $153,045.45.

RxSight Trading Down 0.3 %

NASDAQ:RXST traded down $0.13 during trading hours on Monday, reaching $50.25. The company had a trading volume of 324,504 shares, compared to its average volume of 468,027. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -49.26 and a beta of 1.20. The firm’s 50 day moving average price is $51.91 and its 200-day moving average price is $53.67. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. RxSight’s revenue was up 67.6% compared to the same quarter last year. On average, analysts forecast that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on RXST. Wells Fargo & Company reduced their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. BTIG Research upped their price objective on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Oppenheimer cut their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Finally, Stifel Nicolaus decreased their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight has an average rating of “Buy” and an average price target of $60.14.

Institutional Investors Weigh In On RxSight

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC boosted its holdings in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the last quarter. Nisa Investment Advisors LLC raised its position in RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after acquiring an additional 521 shares during the period. Quest Partners LLC purchased a new position in shares of RxSight during the 2nd quarter worth $41,000. Larson Financial Group LLC bought a new stake in shares of RxSight during the 1st quarter valued at $51,000. Finally, Amalgamated Bank grew its position in shares of RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.